A chronic graft-versus-host disease (GVHD) risk score, used to predict mortality in patients with GVHD, has now been validated by additional analysis of 1,128 patients with chronic GVHD transplanted between 2005 and 2007. These data were reported to CIBMTR (Center for International Blood and Marrow Transplant Research). According to an overall risk score (range, 1 to 12), patients were assigned to 3 risk groups: RG1, RG2, and RG3. Cumulative incidences of non-relapse mortality and overall survival at 5 years after chronic GVHD for each RG were 17% and 72% in RG1, 26% and 53% in RG2, and 44% and 25% in RG3, respectively (all p<0.01). The researchers concluded that these CIBMTR risk groups “can be used to predict major outcomes, tailor treatment planning, and enroll patients in clinical trials.”
Arora M, et al. Biol Blood Marrow Transplant